 |
Video: What is a Stock Split?
|
 |
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. According to our OGEN split history records, Oragenics has had 3 splits. | |
 |

Oragenics (OGEN) has 3 splits in our OGEN split history database. The first split for OGEN took place on January 22, 2018. This was a 1 for 10 reverse split, meaning for each 10 shares of OGEN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. OGEN's second split took place on January 23, 2023. This was a 1 for 60 reverse split, meaning for each 60 shares of OGEN owned pre-split, the shareholder now owned 1 share. For example, a 100 share position pre-split, became a 1.66666666666667 share position following the split. OGEN's third split took place on June 03, 2025. This was a 1 for 30 reverse split, meaning for each 30 shares of OGEN owned pre-split, the shareholder now owned 1 share. For example, a 1.66666666666667 share position pre-split, became a 0.0555555555555556 share position following the split.
When a company such as Oragenics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the OGEN split history from start to finish, an original position size of 1000 shares would have turned into 0.0555555555555556 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Oragenics shares, starting with a $10,000 purchase of OGEN, presented on a split-history-adjusted basis factoring in the complete OGEN split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/21/2015 |
|
End date: |
07/18/2025 |
|
Start price/share: |
$31,320.00 |
|
End price/share: |
$1.35 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-100.00% |
|
Average Annual Total Return: |
-63.40% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$0.43 |
|
Years: |
10.00 |
|
|
 |
Date |
Ratio |
01/22/2018 | 1 for 10 | 01/23/2023 | 1 for 60 | 06/03/2025 | 1 for 30 |
|
 |